592 results about "Anesthetic Agent" patented technology

Sustained release local anesthetic formulations are administered intra articularly and / or into body spaces / cavities. The formulation is preferably a plurality of injectable microparticles including a local anesthetic and an effective amount of a biocompatible, biodegradable, sustained release material prolonging the release of the local anesthetic and optionally and a pharmaceutically acceptable, i.e., non-toxic, augmenting agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable without the augmenting agent.

A formulation for inducing sustained local anesthesia in a patient comprising a substrate comprising a high load of local anesthetic by weight and an effective amount of a biocompatible, controlled release material to obtain a. reversible nerve blockade or anesthesia effect when implanted or injected in a patient, and a non-toxic glucocorticosteroid agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable from the substrate without the glucocorticosteroid agent.

Biocompatible materials are propelled at the skin with sufficient velocity to cause desired resurfacing of skin layers to the desired penetration depth. The materials, such as dry ice or water ice, are harmonious with the human body and thus eliminate foreign body reactions. Various materials may be used in combination, including local anesthetics and vasoconstrictors in solid or liquid form. The biocompatible solid or liquid particles are suspended in a cold carrier fluid and propelled through an insulated delivery system to the surface of the skin. The treatment of diseased skin lesions may be accomplished using the present invention as a drug delivery system.

Implantable or insertable medical devices are provided, which comprises: (a) a biocompatible polymer; and (b) at least one therapeutic agent selected from an anti-inflammatory agent, an analgesic agent, an anesthetic agent, and an antispasmodic agent. The medical devices are adapted for implantation or insertion at a site associated with pain or discomfort upon implantation or insertion. In many embodiments, the therapeutic will be selected from at least one of (i) ketorolac and pharmaceutically acceptable salts thereof (e.g., ketorolac tromethamine) and (ii) 4-diethylamino-2-butynylphenylcyclohexyl glycolate and pharmaceutically acceptable salts thereof (e.g., oxybutynin chloride). Also provided are uses for the implantable or insertable medical devices, which uses comprise reducing pain or discomfort accompanying the implantation or insertion of such devices. Further uses may comprise reducing microbial buildup along the device. Methods for manufacturing implantable or insertable medical devices are also provided.

The invention provides materials, devices and methods for marking biopsy sites for a limited time. The biopsy-marking materials are ultrasound-detectable bio-resorbable powders, with powder particles typically between about 20 microns and about 800 microns in maximum dimension, more preferably between about 300 microns and about 500 microns. The powders may be formed of polymeric materials containing cavities sized between about 10 microns and about 500 microns, and may also contain binding agents, anesthetic agents, hemostatic agents, and radiopaque markers. Devices for delivering the powders include tubes configured to contain the powders and to fit within a biopsy cannula, the powders being ejected by action of a syringe. Systems may include a tube containing powder, and a syringe containing sterile saline. The tube may be configured to fit within a biopsy cannula such as a Mammotome® or SenoCor 360™ cannula.

A formulation for inducing sustained regional local anesthesia in a patient comprising a substrate comprising a local anesthetic and an effective amount of a biocompatible, biodegradable, controlled release material prolonging the release of the local anesthetic from the substrate to obtain a reversible local anesthesia when implanted or injected in a patient, and a non-toxic augmenting agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable from the substrate without the augmenting agent. In preferred embodiments, the controlled release material is a low molecular weight, acid-terminated polymer. A further aspect of the invention is directed to such formulations which release the local anesthetic in two phases, the first a rapid "bolus" to initiate anesthesia and a second, slower release to maintain anesthesia.

An intradermal patch having a permeable backing coated with a polyvinylpyrrolidone-based hydrogel and containing one or more local anesthetics. The patch is breathable, non-irritating upon application and removal, soothing, and sterile. The patch is useful for treating the pain associated with non-intact skin indications.

Disclosed here are effervescent granules having a controllable rate of effervescence. In some embodiments, the such granules comprise an acidic agent, an alkaline agent, a pharmacologically active agent, hot-melt extrudable binder capable of forming a eutectic mixture with the acidic agent and, optionally, a plasticizer. The effervescent granules are made by a hot-melt extrusion process. The present invention also provides a thermal heat process for preparing a pharmacologically active agent containing effervescent granule. In certain aspects, the granules contain pharmacologically active agents such as narcotics, antidiarrheal agents, antiviral agents, anxiolytic agents, a cholesterol lowering agent, an alpha adrenergic blocking agent, a phenanthrene derivative. By way of example, some of the narcotics that may be included in the granules and in the process of preparing the granules include, by way of example: phenanthrene derivatives (e.g., morphine sulfate), and morphine derivatives (e.g., hydromorphone hydrochloride).

Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability and cohesivity, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.

An apparatus for locating and anesthetizing a nerve enables an anesthesiologist to perform a nerve blockade procedure without an assistant. An anesthetic-filled syringe is releasably mounted to a hands-free, foot-actuated, hydraulic syringe controller. An electric current generator is mounted to the syringe controller and operatively connected to a needle of the syringe. A hands-free, foot-actuated current generator controller determines an amperage of an electrical stimulus output to the needle. The current generator includes audible and visual displays for informing the anesthesiologist of the output amperage. Because the syringe controller and current generator controller allow hands-free operation, an anesthesiologist can continuously use both hands to manipulate and hold the needle in a patient.

Embodiments of nanoelectronic sensors are described, including sensors for detecting analytes such as anesthesia gases, CO2 and the like in human breath. An integrated monitor system and disposable sensor unit is described which permits a number of different anesthetic agents to be identified and monitored, as well as concurrent monitoring of other breath species, such as CO2. The sensor unit may be configured to be compact, light weight, and inexpensive. Wireless embodiments provide such enhancements as remote monitoring. A simulator system for modeling the contents and conditions of human inhalation and exhalation with a selected mixture of a treatment agent is also described, particularly suited to the testing of sensors to be used in airway sampling.

A system for measuring a metabolic parameter. The system includes an integrated airway adapter capable of monitoring any combination of respiratory flow, O2 concentration, and concentrations of one or more of CO2, N2O, and an anesthetic agent in real time, breath by breath. Respiratory flow may be monitored with differential pressure flow meters under diverse inlet conditions through improved sensor configurations which minimize phase lag and dead space within the airway. Molecular oxygen concentration may be monitored by way of luminescence quenching techniques. Infrared absorption techniques may be used to monitor one or more of CO2, N2O, and anesthetic agents.

A method and system is provided for monitoring delivery of anesthesia (inhalational and intravenous) and detecting the depth of anesthesia wherein at least one anesthetic agent is absorbed in patient's bloodstream during the administration of anesthesia, which includes sampling inspired and expired gas; analyzing the gas for concentration of at least one substance indicative of the anesthetic agent using sensor technology such as free (unmetabolized) anesthetic agent or its metabolites; determining the effect of the agent based on that concentration; and determining depth of anesthesia based thereon.

The invention provides a system and method utilizing, among other things, fluorescence spectroscopy in the ultraviolet portion of the electromagnetic spectrum to determine chemical species and concentrations. The basic measuring system includes optics, a spectrograph, a detector, and an energy source (“head” components), along with a computer and control electronics and power source capable of generating and detecting unique fluorescence signatures for individual and unique mixtures of chemical substances including, for example, prescribed and / or compounded medications, alcohol products, food types, synthetic drugs, narcotics, perfumes, liquids, and the like.

A method and system for objectively scoring intra-operative pain during general anaesthesia based on the patient's mean arterial pressure and heart rate. The index is used for closed-loop control of the intra-operative analgesia through adjustment of the drug infusion level according to fuzzy logic. It is further displayed along with other components of anaesthesia and important patient data on a monitoring display for presentation to medical staff.

A method for monitoring anesthetization of a patient, includes the steps of removably connecting a plurality of electrodes to the scalp of the patient and administering sufficient anesthesia to the patient so that the patient attains a plane of anesthesia selected by an operator. The brain waves of the patient are then amplified and digitized after the patient has been anesthetized, before beginning the medical procedure, to obtain a first set of digital data. The brain waves of the patient are then amplified and digitized during the medical procedure to provide a second set of digital data and the first and second sets of digital data are analyzed in at least one of a time domain and a frequency domain. Separate trajectories are then computed from the data analysis trajectories for at least two different indices of an anesthetic state of the patient during the medical procedure, the indices being selected from a group including a Depth Index (DI), a Memory Index (MI) and a Pain Index (PI). A system for providing anesthesia to a patient, includes a plurality of electrodes, a first arrangement allowing an operator to administer anesthesia to the patient until the patient has attained a selected plane of anesthesia and a second arrangement coupled to the electrodes for amplifying and digitizing brain waves of the patient after the patient has been anesthetized, before the medical procedure has been begun to obtain a first set of digital data, the second arrangement amplifying and digitizing ongoing brain waves of the patient during the medical procedure to provide a second set of digital data in combination with a third arrangement analyzing the first and second sets of digital data in at least one of a time domain and a frequency domain, a fourth arrangement computing from the data analysis separate trajectories for at least two different indices of a state of the patient during the medical procedure, the indices being selected from a group including a Depth Index (DI), a Memory Index (MI) and a Pain Index (PI), a fifth arrangement providing control signals when any of the trajectories indicates that the patient is deviating from the selected plane of anesthesia and a sixth arrangement automatically adjusting two different anesthetic agents administered to the patient based on the control signal to restore the patient to the selected plane of anesthesia.

An integrated airway adapter capable of monitoring any combination of respiratory flow, O2 concentration, and concentrations of one or more of CO2, N2O, and an anesthetic agent in real time, breath by breath. Respiratory flow may be monitored with differential pressure flow meters under diverse inlet conditions through improved sensor configurations which minimize phase lag and dead space within the airway. Molecular oxygen concentration may be monitored by way of luminescence quenching techniques. Infrared absorption techniques may be used to monitor one or more of CO2, N2O, and anesthetic agents.

The invention provides materials, devices and methods for marking biopsy sites for a limited time. The biopsy-marking materials are ultrasound-detectable bio-resorbable powders, with powder particles typically between about 20 microns and about 800 microns in maximum dimension, more preferably between about 300 microns and about 500 microns. The powders may be formed of polymeric materials containing cavities sized between about 10 microns and about 500 microns, and may also contain binding agents, anesthetic agents, hemostatic agents, and radiopaque markers. Devices for delivering the powders include tubes configured to contain the powders and to fit within a biopsy cannula, the powders being ejected by action of a syringe. Systems may include a tube containing powder, and a syringe containing sterile saline. The tube may be configured to fit within a biopsy cannula such as a Mammotome® or SenoCor 360™ cannula.

A pharmaceutically delivery system and method of use therefor are described comprising a pharmaceutically active agent and acidified nitrite as an agent to produce local production of nitric oxide at the skin surface. The dosage form may be in any pharmaceutically acceptable carrier means and comprises an acidifying agent adapted to reduce the pH at the environment. In one embodiment, a barrier consisting of a membrane allows diffusions of the anaesthetic and nitrite ions while preventing direct contact of the skin and acidifying agent.

The invention generally relates to a continuous anesthesia nerve conduction apparatus and method thereof, and more particularly to a method and system for use in administering a continuous flow or intermittent bolus of anesthetic agent to facilitate a continuous or prolonged nerve block. In one embodiment, the apparatus includes a sheath having a proximal end, a distal end and at least one lumen extending from the proximal end to the distal end. The sheath also includes an embedded conductive element for transmitting an electrical signal from a proximal portion of the sheath to a distal portion of the sheath. A cannula is arranged in the at least one lumen of the sheath and has a distal end protruding from a distal portion of the sheath. The cannula is electrically coupled to at least a portion of the embedded conductive element and is configured to provide nerve stimulation.

The invention generally relates to a continuous anesthesia nerve conduction apparatus and method thereof, and more particularly to a method and system for use in administering a continuous flow or intermittent bolus of anesthetic agent to facilitate a continuous or prolonged nerve block. In one embodiment, the apparatus includes a sheath having a proximal end, a distal end and at least one lumen extending from the proximal end to the distal end. The sheath also includes an embedded conductive element for transmitting an electrical signal from a proximal portion of the sheath to a distal portion of the sheath. A cannula is arranged in the at least one lumen of the sheath and has a distal end protruding from a distal portion of the sheath. The cannula is electrically coupled to at least a portion of the embedded conductive element and is configured to provide nerve stimulation.

An electronic anesthesia delivery apparatus having a chassis including a first anesthetic agent chamber and a second anesthetic agent chamber, each of the first and second chambers including an anesthetic agent therein. At least one electronically controlled valve is in fluid communication with each of the first agent chamber and the second agent chamber and an oxygen source. The oxygen source is in fluid communication with each of the at least one electronically controlled valves. A touchscreen graphic display having controls corresponding to each of the at least one electronically controlled valves for controlling flow rate and concentration of anesthesia.